Researcher Spotlight: Discovering a Passion for Teaching and Breast Cancer Research
November 19, 2026Emmalyn Lecky, a PhD candidate at Harvard University, is exploring new drug combinations that could slow breast cancer growth and lead to more effective treatment strategies.
When teaching her first class, Emmalyn Lecky realized she had seriously underestimated the hard work that goes into preparing and giving a college lecture.
“I definitely didn’t give my teachers enough credit,” she said. “This was a turning point for me because it inspired me to pursue teaching as a future career.”
Lecky traces her own path into science back to encouraging teachers in high school and an early opportunity to work in a lab. “That really showed me the day-to-day of being a scientist,” she said. “It was pretty life-changing because that made me decide to major in biology and pursue a research career.”
Now a PhD student at Harvard Medical School, Lecky received the PhRMA Foundation Predoctoral Fellowship in Drug Discovery for her research developing new treatment strategies for breast cancer by targeting a cellular signaling pathway called AKT, which is often overactive in tumors.
While drugs have been designed to shut down this pathway, they have frequently fallen short due to side effects and drug resistance. Lecky’s work takes a different approach, pairing these existing drugs with complementary therapies that target different cell components.
The laboratory that Lecky works in discovered that AKT may directly regulate a system that places chemical tags on RNA, the molecules that carry genetic instructions used to make proteins. These tags influence how cells use genetic information and may help cancer cells thrive. Drugs targeting this RNA tagging system have already entered early clinical trials.
Combining drugs that block AKT and this tagging system slows cancer cell growth far more than either drug alone. “What excites me is trying to understand why these drugs work so well together,” Lecky said. Her research investigates how AKT controls RNA tagging, how this interaction affects tumor growth, and how the combination treatment works in preclinical tumor models.
Beyond the laboratory, Lecky’s teaching responsibilities have played an important role in her development as a scientist. “It’s not enough to just understand science,” she said. “You need to be able to explain your science and get other people excited about it, too.”
Lecky believes that helping people understand the scientific process is critical to building public confidence in research. Scientific knowledge evolves as researchers gather new evidence, test ideas, and refine their understanding. She referenced the evolving guidelines during the COVID-19 pandemic as an example. “Changing recommendations isn’t a sign that science failed,” she said. “It’s a sign that science is working.”
Lecky values the creativity and problem-solving involved in research, but what she loves most is the people she gets to work with. “My coworkers are some of the most like inspiring and fun people who care really deeply about doing good science,” she said.
While Lecky loves doing research, she also recognizes the importance of maintaining balance in a demanding scientific career. Outside the lab, she enjoys spending time with friends and family, running around Boston, trying new restaurants, and attending concerts.
One piece of advice she got early on in her career journey has stayed with her: Prioritize your physical and mental well-being. “It’s really important to take breaks,” Lecky said. “It’s important to seek out help when you need it and to have a good work-life balance outside of lab.”
Looking ahead, Lecky hopes to continue developing new cancer therapies, whether in academia or industry. She also plans to keep teaching, combining two passions that have shaped her journey from the beginning: advancing science and helping others learn.